For Immediate Assistance Call 1-800-966-2244
Mesothelioma News

Biotech Company Announces Promising Phase 1 Mesothelioma Test Results

Mesothelioma researchers attending last week’s International Association for the Study of Lung Cancer (ASLC) 19th World Conference on Lung Cancer attended the gathering with high hopes for breakthroughs in fighting the challenging disease, and they did not leave disappointed. Among the most promising news that the group heard was of groundbreaking results achieved by Aldeyra Therapeutics, Inc. in a Phase 1/2 clinical trial of their drug ADX-1612 (ganetespib).

ADX-1612 is a selective inhibitor of heat shock protein 90,  a protein that facilitates the excessive and uncontrolled cell replication seen in cancers like malignant mesothelioma. The drug is also being tested on ovarian cancer, but its mesothelioma testing has focused on what happens when it is used in combination with the standard mesothelioma chemotherapy protocol of pemetrexed and platinum. Though the company has only completed its Phase 1/2 testing on a small group with the goal of determining safety, tolerability and efficacy, the company was pleased to report that the study delivered a 61% positive response, representing a significant improvement over previous attempts to supplement the standard treatment.

The study was done as part of the UKMESO-2 clinical trial, and Professor Dean Fennell MD PhD, Chief Investigator of the trial said, “The MESO-2 results are highly encouraging. Addition of ADX-1612 to pemetrexed and either cisplatin or carboplatin achieved an overall response rate of 61%, the highest seen to date for addition of a novel agent to front-line chemotherapy. Hsp90 inhibition could represent a new advance for the treatment of mesothelioma.”

The mesothelioma trial investigating ADX-1612 involved 27 patients that were provided with the supplemental medication on two days during the three-week period of their chemotherapy treatment. After the test, 22 patients showed a positive clinical response and only one had their disease progress. Of those that showed improvement seven exhibited a reduction in their tumor burden of 50% or more, while one had a 37-month period without disease progression. All patients tolerated the therapy well.

For mesothelioma patients, news of a positive result like this are very encouraging and offer great hope for the future. Other positive news can come from legal advocates. If you need information on how we can help, contact us at 1-800-966-2244.